Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
Top Cited Papers
- 1 November 2016
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 28 (2), 292-297
- https://doi.org/10.1093/annonc/mdw559
Abstract
Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0–2. The primary endpoint was the objective response rate. A total of 18 patients were enrolled in this study between July 2013 and October 2015. Patients were aged 35–71 years; three had a performance status of 2, and the majority were a heavily pretreated population (≥ two different previous chemotherapy regimens in 72% of the patients). Among the 17 evaluable patients, three had a partial response (objective response rate = 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months. The safety profile was comparable with previous studies of vandetanib. Most vandetanib-related adverse events were mild with prevalent hypertension and rash (in >70% of patients). Grade 3 toxicity included hypertension (n = 3), QT prolongation (2), and elevation of aminotransferases (1), and as a consequence the dose was reduced in four patients. There were no adverse events associated with grade 4 or 5 toxicity. Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements.Keywords
Funding Information
- Seoul National University Hospital Research Fund (05-2012-0030)
This publication has 28 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?Journal of Clinical Oncology, 2013
- The transcriptional landscape and mutational profile of lung adenocarcinomaGenome Research, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- KIF5B-RET fusions in lung adenocarcinomaNature Medicine, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Research, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989